Last reviewed · How we verify

NCT00958425

Intraoperative Hyaluronic Acid Gel Injection for Improvement of Scar Quality Following Reduction Mammaplasty

Withdrawn Phase 3 Last updated 21 August 2024
What this trial tests

Phase 3 trial testing Hyaluronic acid gel in Cicatrix. Withdrawn.

Timeline
1 January 2014
Primary endpoint
1 January 2014
1 January 2014

Quick facts

Lead sponsorNova Scotia Health Authority
PhasePhase 3
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Start date1 January 2014
Primary completion1 January 2014
Estimated completion1 January 2014

Drugs / interventions tested

Conditions studied

Sponsor

Nova Scotia Health Authority — full company profile →

Who can join

18 and older, female only, with Cicatrix. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the efficacy of hyaluronic acid gel injections compared to saline injections in improving scar quality in patients undergoing breast reduction surgery. Hyaluronic acid has been implicated in scarless fetal healing, and the investigators therefore hypothesize that injections of hyaluronic acid gel into breast reduction incisions will improve their appearance compared to injections of saline.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Modelling and targeting mechanical forces in organ fibrosis.
    Mascharak S, Guo JL, Griffin M, Berry CE, et al · · 2024 · cited 23× · PMID 39552705 · DOI 10.1038/s44222-023-00144-3

Verify or expand the search:

Other trials of Hyaluronic acid gel

Trials testing the same drug.

Other recruiting trials for Cicatrix

Currently open trials in the same condition.

Other Nova Scotia Health Authority trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00958425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing